Aktuellt
SENASTE
Redeye provides its initial comment on Sedana Medical’s Q3 report. Sales came in 10% below our forecast, but good cost control demonstrates the company’s ability to continue growing whilst overlooking its OPEX. We will shortly return with a more detailed take on the report in a coming update.
LÄS MER
